Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease.
Conor BellParul TandonEric LentzJohn K MarshallNeeraj NarulaPublished in: Journal of gastroenterology and hepatology (2021)
Our systematic review highlights possible concern with the general safety of vedolizumab in pregnancy, as an increase in overall total unfavorable outcomes was observed. Premature births and early loss of pregnancy were also more prevalent in pregnant female patients on vedolizumab. It is possible these findings are confounded by disease activity, and further prospective cohort studies of vedolizumab and pregnancy outcomes are warranted.
Keyphrases
- patients with inflammatory bowel disease
- pregnancy outcomes
- disease activity
- systematic review
- pregnant women
- rheumatoid arthritis
- systemic lupus erythematosus
- ulcerative colitis
- end stage renal disease
- rheumatoid arthritis patients
- preterm birth
- chronic kidney disease
- ejection fraction
- ankylosing spondylitis
- newly diagnosed
- meta analyses
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- adipose tissue
- weight loss
- patient reported